Ryan's District Boards

<p><a href="http://news.yahoo.com/pfizers-deal-looms-larger-earnings-report-053649406--finance.html"><img src="http://l.yimg.com/bt/api/res/1.2/qRr5tOXy6WgcxDUNrTpztg--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-07-28T053649Z_1_LYNXMPEA6R04D_RTROPTP_2_ASTRAZENECA-PFIZER.JPG" width="130" height="86" alt="The Pfizer logo is seen at their world headquarters in New York" align="left" title="The Pfizer logo is seen at their world headquarters in New York" border="0" /></a>By Ransdell Pierson NEW YORK (Reuters) - Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline. While many industry watchers expect Pfizer to re-engage with Britain's AstraZeneca in coming months, some say the U.S. drugmaker should consider targets more focused on biotechnology, a strategy that has paid off for Merck &amp; Co and Bristol-Myers Squibb Co. Although Pfizer is conducting trials of promising products - including breast cancer drug palbociclib and vaccines against meningitis and staph aureus - it needs far more drugs to generate meaningful sales growth, said Ori Hershkovitz, analyst with the Tel Aviv-based Sphera Fund, which holds Pfizer shares.     &quot;Pfizer is in a very desperate spot, having seen most of its pipeline disappoint and facing multiple patent expirations,&quot; he said.</p><br clear="all"/>